Market Cap 10.88B
Revenue (ttm) 4.44B
Net Income (ttm) 338.00M
EPS (ttm) N/A
PE Ratio 22.91
Forward PE 23.71
Profit Margin 7.61%
Debt to Equity Ratio 0.60
Volume 3,663,800
Avg Vol 5,253,944
Day's Range N/A - N/A
Shares Out 496.86M
Stochastic %K 14%
Beta 1.86
Analysts Strong Sell
Price Target $24.55

Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. It offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Crede...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 877 352 6261
Address:
2500 Innovation Way, Greenfield, United States
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 6 at 2:25 AM
Actionable Trade Alert for $ELAN: Market Context: $ELAN is currently trading at $21.99, with an RSI of 50.0 indicating a neutral momentum. The stock is positioned between its 60-day high of $23.7 and low of $18.22, suggesting potential for movement in either direction. Directional Bias: The price is above the 50-day moving average (MA50) of $21.5, indicating a bullish sentiment, while the 30-day moving average (MA30) at $22.2 provides additional support. The neutral RSI suggests that the stock could break out or retrace, but the proximity to the MA30 may favor upward movement. Trade Plan: - Suggested Entry: $22.00 - Stop Loss: $20.50 (2.3% risk) - Take Profit Targets: 1. $23.00 (4.5% gain) 2. $23.50 (6.8% gain) 3. $25.00 (13.6% gain, 17% ROI from entry) This plan offers a solid risk-reward ratio with a potential for over 17% ROI on the third target. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 5 at 9:59 PM
Actionable Trade Alert for $ELAN: Market Context: $ELAN is currently trading at $21.99, with an RSI of 50.0 indicating a neutral momentum. The stock is positioned between its 60-day high of $23.7 and low of $18.22, suggesting potential for movement in either direction. Directional Bias: The price is above the 50-day moving average (MA50) of $21.5, indicating a bullish sentiment, while the 30-day moving average (MA30) at $22.2 provides additional support. The neutral RSI suggests that the stock could break out or retrace, but the proximity to the MA30 may favor upward movement. Trade Plan: - Suggested Entry: $22.00 - Stop Loss: $20.50 (2.3% risk) - Take Profit Targets: 1. $23.00 (4.5% gain) 2. $23.50 (6.8% gain) 3. $25.00 (13.6% gain, 17% ROI from entry) This plan offers a solid risk-reward ratio with a potential for over 17% ROI on the third target. https://privateprofiteers.com
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 4 at 2:40 AM
$ELAN Current Stock Price: $22.18 Contracts to trade: $20 ELAN Dec 19 2025 Call Entry: $1.45 Exit: $1.82 ROI: 25% Hold ~20 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Peaceouty
Peaceouty Nov. 25 at 5:49 PM
0 · Reply
Trader_Ty
Trader_Ty Nov. 25 at 3:17 PM
$ELAN looks like a 9 ride in progress
0 · Reply
GettnFibbywIT
GettnFibbywIT Nov. 25 at 7:41 AM
$ELAN $XPH Elanaco Animal Health, INC / (ELAN) - Daily:
0 · Reply
topstockalerts
topstockalerts Nov. 21 at 8:25 PM
Elanco Animal Health shares gained Friday after the FDA granted Emergency Use Authorization for Credelio CAT, a treatment aimed at protecting cats from New World screwworm infestations. It marks the first emergency approval in the U.S. for treating this parasite in felines, as cases have been detected close to the U.S.–Mexico border. The decision follows a similar authorization last month for dogs. Elanco said the rapid review highlights strong scientific evidence of Credelio CAT’s potential effectiveness and provides veterinarians a critical option should the invasive fly spread further into the U.S., where even small wounds can attract screwworm eggs. $ELAN
0 · Reply
notreload_ai
notreload_ai Nov. 21 at 7:52 PM
$ELAN ... The FDA issued an emergency authorization for Credelio CAT (lotilaner) to treat dangerous New World Screwworm (NWS) in cats, preparing the U.S. for this emerging health threat. https://notreload.xyz/fda-grants-historic-eua-for-elanco-credelio-cat/
0 · Reply
acborg
acborg Nov. 21 at 7:46 PM
$ELAN I’ve held to this stock from when my previously owned ‘Aratana Therapeutics’ shares where sold out to Elanco for so cheap that I had lost so much. I’ve been hoping for so long that Elanco at least touches $40 for me to at least break even. Finally a move in the right direction but I doubt I’ll see it go up by another $20 anytime in the close future.
0 · Reply
JarvisFlow
JarvisFlow Nov. 21 at 3:01 PM
Keybanc has updated their rating for Elanco Animal Health ( $ELAN ) to Overweight with a price target of 27.
0 · Reply
Latest News on ELAN
Elanco executive appointed as Neurizon's Board Observer

Nov 26, 2025, 6:15 PM EST - 10 days ago

Elanco executive appointed as Neurizon's Board Observer


Elanco Animal Health Stock Is Undervalued: Analyst

Nov 21, 2025, 1:21 PM EST - 15 days ago

Elanco Animal Health Stock Is Undervalued: Analyst


Elanco to Participate in the Upcoming Investor Conferences

Nov 20, 2025, 8:00 AM EST - 17 days ago

Elanco to Participate in the Upcoming Investor Conferences


6 Healthcare Stocks With Strong Upward Momentum

Nov 18, 2025, 12:59 PM EST - 18 days ago

6 Healthcare Stocks With Strong Upward Momentum

ABVX CAH GH MEDP WGS


Elanco Animal Health Reports Third Quarter 2025 Results

Nov 5, 2025, 6:27 AM EST - 4 weeks ago

Elanco Animal Health Reports Third Quarter 2025 Results


Elanco to Host Investor Day on December 9

Oct 16, 2025, 4:32 PM EDT - 7 weeks ago

Elanco to Host Investor Day on December 9


Elanco (ELAN) Q2 Revenue Jumps 5%

Aug 7, 2025, 7:18 AM EDT - 4 months ago

Elanco (ELAN) Q2 Revenue Jumps 5%


Elanco Animal Health Reports Second Quarter 2025 Results

Aug 7, 2025, 6:27 AM EDT - 4 months ago

Elanco Animal Health Reports Second Quarter 2025 Results


Elanco's dog flu vaccine gets USDA nod

Jul 9, 2025, 10:01 AM EDT - 5 months ago

Elanco's dog flu vaccine gets USDA nod


Elanco Releases 2024 Impact Report and Introduces New Framework

Jun 26, 2025, 1:00 PM EDT - 5 months ago

Elanco Releases 2024 Impact Report and Introduces New Framework


Elanco: Deleveraging Takes Time

May 12, 2025, 4:26 AM EDT - 7 months ago

Elanco: Deleveraging Takes Time


Elanco Animal Health Reports First Quarter 2025 Results

May 7, 2025, 6:27 AM EDT - 7 months ago

Elanco Animal Health Reports First Quarter 2025 Results


PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 6 at 2:25 AM
Actionable Trade Alert for $ELAN: Market Context: $ELAN is currently trading at $21.99, with an RSI of 50.0 indicating a neutral momentum. The stock is positioned between its 60-day high of $23.7 and low of $18.22, suggesting potential for movement in either direction. Directional Bias: The price is above the 50-day moving average (MA50) of $21.5, indicating a bullish sentiment, while the 30-day moving average (MA30) at $22.2 provides additional support. The neutral RSI suggests that the stock could break out or retrace, but the proximity to the MA30 may favor upward movement. Trade Plan: - Suggested Entry: $22.00 - Stop Loss: $20.50 (2.3% risk) - Take Profit Targets: 1. $23.00 (4.5% gain) 2. $23.50 (6.8% gain) 3. $25.00 (13.6% gain, 17% ROI from entry) This plan offers a solid risk-reward ratio with a potential for over 17% ROI on the third target. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 5 at 9:59 PM
Actionable Trade Alert for $ELAN: Market Context: $ELAN is currently trading at $21.99, with an RSI of 50.0 indicating a neutral momentum. The stock is positioned between its 60-day high of $23.7 and low of $18.22, suggesting potential for movement in either direction. Directional Bias: The price is above the 50-day moving average (MA50) of $21.5, indicating a bullish sentiment, while the 30-day moving average (MA30) at $22.2 provides additional support. The neutral RSI suggests that the stock could break out or retrace, but the proximity to the MA30 may favor upward movement. Trade Plan: - Suggested Entry: $22.00 - Stop Loss: $20.50 (2.3% risk) - Take Profit Targets: 1. $23.00 (4.5% gain) 2. $23.50 (6.8% gain) 3. $25.00 (13.6% gain, 17% ROI from entry) This plan offers a solid risk-reward ratio with a potential for over 17% ROI on the third target. https://privateprofiteers.com
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 4 at 2:40 AM
$ELAN Current Stock Price: $22.18 Contracts to trade: $20 ELAN Dec 19 2025 Call Entry: $1.45 Exit: $1.82 ROI: 25% Hold ~20 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Peaceouty
Peaceouty Nov. 25 at 5:49 PM
0 · Reply
Trader_Ty
Trader_Ty Nov. 25 at 3:17 PM
$ELAN looks like a 9 ride in progress
0 · Reply
GettnFibbywIT
GettnFibbywIT Nov. 25 at 7:41 AM
$ELAN $XPH Elanaco Animal Health, INC / (ELAN) - Daily:
0 · Reply
topstockalerts
topstockalerts Nov. 21 at 8:25 PM
Elanco Animal Health shares gained Friday after the FDA granted Emergency Use Authorization for Credelio CAT, a treatment aimed at protecting cats from New World screwworm infestations. It marks the first emergency approval in the U.S. for treating this parasite in felines, as cases have been detected close to the U.S.–Mexico border. The decision follows a similar authorization last month for dogs. Elanco said the rapid review highlights strong scientific evidence of Credelio CAT’s potential effectiveness and provides veterinarians a critical option should the invasive fly spread further into the U.S., where even small wounds can attract screwworm eggs. $ELAN
0 · Reply
notreload_ai
notreload_ai Nov. 21 at 7:52 PM
$ELAN ... The FDA issued an emergency authorization for Credelio CAT (lotilaner) to treat dangerous New World Screwworm (NWS) in cats, preparing the U.S. for this emerging health threat. https://notreload.xyz/fda-grants-historic-eua-for-elanco-credelio-cat/
0 · Reply
acborg
acborg Nov. 21 at 7:46 PM
$ELAN I’ve held to this stock from when my previously owned ‘Aratana Therapeutics’ shares where sold out to Elanco for so cheap that I had lost so much. I’ve been hoping for so long that Elanco at least touches $40 for me to at least break even. Finally a move in the right direction but I doubt I’ll see it go up by another $20 anytime in the close future.
0 · Reply
JarvisFlow
JarvisFlow Nov. 21 at 3:01 PM
Keybanc has updated their rating for Elanco Animal Health ( $ELAN ) to Overweight with a price target of 27.
0 · Reply
GettnFibbywIT
GettnFibbywIT Nov. 14 at 7:54 PM
$ELAN $XPH Elanco Animal Health (XPH)- Wait a minute, a pull back at the technical 50% Fib level of the July '21 to May '23 draw down level, with a price + momentum divergence developing - Who knew? Coincidence perhaps......I think not:
0 · Reply
Patstock
Patstock Nov. 12 at 12:37 PM
$ELAN it is eating $ZTS lunch. First simparica trio got hit and now they are aiming for Cytopoint inj
0 · Reply
Trader_Ty
Trader_Ty Nov. 10 at 2:07 AM
$ELAN IPO double bottom. Maybe a run to ATHs
0 · Reply
JarvisFlow
JarvisFlow Nov. 6 at 5:35 PM
UBS has updated their rating for Elanco Animal Health ( $ELAN ) to Buy with a price target of 27.
0 · Reply
DonCorleone77
DonCorleone77 Nov. 5 at 11:51 AM
$ELAN Elanco reports Q3 EPS 19c, consensus 13c -- Q3 revenue $1.14B, consensus $1.09B -- Raises FY25 adjusted EPS view to 91c-94c, consensus 91c -- Raises FY25 revenue view to $4.65B-$4.67B from $4.57B-$4.62B, consensus $4.6B. -- Raises FY25 adjusted EBITDA view to $880M-$900M from $850M-$890M. -- Sees Q4 adjusted EPS 9c-12c, consensus 14c -- Sees Q4 revenue $1.09B-$1.11B, consensus $1.08B. -- Sees Q4 adjusted EBITDA $168M-$188M.
0 · Reply
lecorb
lecorb Nov. 5 at 11:43 AM
$ELAN Elanco press release (ELAN): Q3 Non-GAAP EPS of $0.19 beats by $0.06. Revenue of $1.X.14B (+10.7% Y/Y) beats by $50M. Full Year 2025 Guidance: Raising revenue guidance to $4.X,645 million to $4.X,670 million; expect accelerating organic constant currency revenue growth of 6% to 6.5% vs. 3% in 2024 Raising 2025 innovation revenue target by $100 million at the midpoint of the range to $840 to $880 million Reported Net Loss of $56 million to $41 million, raising guidance for Adjusted EBITDA to $880 million to $900 million Reported Loss Per Share of $0.11 to $0.08, raising guidance for Adjusted EPS to $0.91 to $0.94 2025 year-end net leverage ratio target improved to 3.7x to 3.8x, enabled by year-to-date execution and disciplined working capital management
0 · Reply
BeanSupreme
BeanSupreme Nov. 4 at 4:58 PM
$ZTS Big fears here that they are losing market share to $ELAN
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Oct. 31 at 11:43 AM
$ELAN RSI: 91.94, MACD: 0.8441 Vol: 0.92, MA20: 21.15, MA50: 19.68 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
OptionRunners
OptionRunners Oct. 29 at 5:43 PM
$ELAN Buyer of the January 16th 2026 $20 puts 4,750 times for $1.X.07 against OI of 4,918 contracts. Appears to be adding, check the change in OI for confirmation. Earnings on 11/5
0 · Reply
OptionRunners
OptionRunners Oct. 28 at 2:57 PM
$ELAN Buyer of the January 16th 2026 $20 puts 3,500 times for $1.04 ahead of earnings on 11/5
0 · Reply
LtFrankDrebin
LtFrankDrebin Oct. 26 at 8:30 PM
$ELAN Elanco received an emergency-use authorization for it's screwworm treatment, the first time this authorization has happened for an animal drug. This is because this is much bigger than treating a pet worm, since the FDA said this parasite poses a threat to livestock and food security near the US-Mexico border, as reported by the WSJ. https://www.wsj.com/health/healthcare/elanco-animal-health-obtains-fda-authorization-for-screwworm-treatment-c5566ad7
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Oct. 24 at 9:42 PM
0 · Reply